Affimed GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
Sep 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for Anti-CD16 binding molecules (US 9,035,026) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,035,026 | Anti-CD16 binding molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 10,273,309 | Antibody binding sites specific for EGFRvIII In force · From the USPTO record | In force | From the USPTO record | |
| US 10,066,015 | CD3 binding domains In force · From the USPTO record | In force | From the USPTO record | |
| US 11,167,029 | Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 11,535,672 | Combination of an ANTI-CD16A Antibody with a Cytokine In force · High confidence | In force | High confidence | |
| US 11,180,558 | Tandem diabody for CD16A-directed NK-cell engagement In force · From the USPTO record | In force | From the USPTO record | |
| US 11,572,415 | Multivalent FV Antibodies In force · High confidence | In force | High confidence | |
| US 12,076,384 | Bispecific EGFR/CD16 antigen-binding protein In force · From the USPTO record | In force | From the USPTO record | |
| US 11,001,633 | NK Cell Engaging Antibody Fusion Constructs In force · High confidence | In force | High confidence | |
| US 11,510,972 | Bispecific EGFR/CD16 Antigen-Binding Protein In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 1 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 abandoned · 4 no status recorded